Primary prophylaxis with low-molecular weight heparin, heparin, or warfarin is often considered in known familial cases. Anticoagulant prophylaxis is given to all who develop a venous clot regardless of underlying cause. Studies have demonstrated an increased risk of recurrent venous thromboembolic events in patients with<unk> . Therefore, long-term anticoagulation therapy with warfarin may be considered in these patients. Homozygous protein C defect constitutes a potentially life-threatening disease, and warrants the use of supplemental protein C concentrates. Liver transplant may be considered curative for homozygous<unk> .
Protein C deficiency
Activated protein C resistance
Factor VII deficiency
Protein S deficiency
COAT platelet defect
Factor XIII deficiency
Factor XII deficiency
Antithrombin III deficiency